Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 5;4(1):36-44.
doi: 10.1016/j.ncrna.2019.01.003. eCollection 2019 Mar.

Long non-coding RNAs: Functional regulatory players in breast cancer

Rana Ahmed Youness  1 , Mohamed Zakaria Gad  2
Affiliations
Review

Long non-coding RNAs: Functional regulatory players in breast cancer

Rana Ahmed Youness et al. Noncoding RNA Res. .

Erratum in

Abstract

Historically, the long-held protein-centered bias has denoted 98% of the human genome as 'Junk' DNA. However, the current work has shifted the perception of such 'junk' transcriptional products to functional regulatory molecules. The recent surveillance of the human transcriptome has highlighted the pivotal role of such non-coding RNA (ncRNA) molecules in diverse physiological and pathological conditions. Long non-coding RNA (lncRNA) is a recent class of ncRNA molecules that is still in its infancy stage. The main focus of this review is to unravel the importance of lncRNAs in the most prevalent malignancy among females which is Breast Cancer (BC). A specific focus on lncRNAs as prognostic markers among BC patients showing molecular subtype heterogeneity was also tackled in this review. Finally, the functional and the mechanistic roles of such booming ncRNA molecules in shaping the fate of the BC progression have been highlighted.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Molecular signaling pathways underlying breast cancer.
Fig. 2
Fig. 2
Association of long-non-coding RNA molecules with different hallmarks of cancer.
See this image and copyright information in PMC

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Canc. 2015;136(5):E359–E386. - PubMed
    1. Yousef E.M., Furrer D., Laperriere D.L., Tahir M.R., Mader S., Diorio C., Gaboury L.A. MCM2: an alternative to Ki-67 for measuring breast cancer cell proliferation. Mod. Pathol. 2017;30(5):682–697. - PubMed
    1. Turashvili G., Brogi E. Tumor heterogeneity in breast cancer. Front. Med. 2017;4:227. - PMC - PubMed
    1. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., Perou C.M. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006;19(2):264–271. - PubMed
    1. Youness R.A., Assal R.A., Abdel Motaal A., Gad M.Z. A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression. Nitric Oxide. 2018;80:12–23. - PubMed

LinkOut - more resources